Cellectis (CLLS) Net Cash Flow Growth (1y) (2016 - 2026)
Cellectis (CLLS) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
-55.49% |
| Date | Value |
|---|
| Mar 31, 2026 |
-55.49% |
| Dec 31, 2025 |
157.69% |
| Sep 30, 2025 |
-175.47% |
| Jun 30, 2025 |
-377.39% |
| Mar 31, 2025 |
-26.41% |
| Dec 31, 2024 |
-119.31% |
| Sep 30, 2024 |
178.22% |
| Jun 30, 2024 |
2,321.70% |
| Mar 31, 2024 |
-61.98% |
| Dec 31, 2023 |
573.41% |
| Sep 30, 2023 |
48.03% |
| Jun 30, 2023 |
95.15% |
| Mar 31, 2023 |
72.20% |
| Dec 31, 2022 |
55.25% |
| Sep 30, 2022 |
17.34% |
| Jun 30, 2022 |
-155.75% |
| Mar 31, 2022 |
2.97% |
| Dec 31, 2021 |
-202.10% |
| Sep 30, 2021 |
-438.77% |
| Jun 30, 2021 |
246.44% |
